• Meta analysis using the most serious outcome reported shows 15% [-57‑54%] improvement, without reaching statistical significance. Results are worse for Randomized Controlled Trials and similar for peer-reviewed studies. Results are consistent with early treatment being more effective than late treatment.
• 4 studies from 4 independent teams in 2 different countries show statistically significant improvements in isolation (1 for the most serious outcome).
• Efficacy is variant dependent. In Vitro
studies suggest lower efficacy for omicron BA.1 [Liu, Sheward, VanBlargan] and no efficacy for omicron BA.2 [Zhou]. US EUA has been revoked. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary].
• While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 43% of sotrovimab studies show zero events in the treatment arm. Multiple treatments are typically used in combination, and other treatments are significantly more effective.
• No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.
• All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., 8/12/2022, preprint, 1 author.